Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US)-Reference-Cited by-同舟云学术

Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US)

Published:2023-09 Issue:40 Volume:41 Page:5820-5824
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Nelson Christopher B.^ORCID,Brady Brenna L.,Richards Megan,Lew Carolyn R.,Via William La,Greenberg Michael,Rizzo Christopher

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference23 articles.

1. Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009–2019: a study of the national (nationwide) inpatient sample;Suh;J Infect Dis,2022

2. Centers for Disease Control and Prevention. CDC HAN-00443: Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States, https://emergency.cdc.gov/han/2021/han00443.asp [accessed 20 December 2022].

3. Respiratory syncytial virus during the COVID-19 pandemic compared to historic levels: a retrospective cohort study of a health system;Movva;J Infect Dis,2022

4. Centers for Disease Control and Prevention. CDC HAN-00479: Increased Respiratory Virus Activity, Especially Among Children, Early in the 2022-2023 Fall and Winter, https://emergency.cdc.gov/han/2022/han00479.asp [accessed 20 December 2022].

5. Wood C, Walter E, Espinosa C, Enriquez-Bruce M, Budhecha S, Elliott A, et al. Infant hospitalizations and ICU admissions for bronchiolitis and RSV-bronchiolitis are at historic highs during 2022 early seasonal disease: results from four US health systems. The Pediatric Academic Societies (PAS) Meeting, April 27 – May 1, 2023. Washington, D.C. USA.